Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals

AIDS Research and Human Retroviruses

Volumn 15, Issue 12, 1999, Pages 1063-1071

  Derdeyn, Cynthia A ^a   Costello, Caroline ^a   Kilby, J Michael ^b   Sfakianos, Greg ^b   Saag, Michael S ^b   Kaslow, Richard ^a   Bucy, R Pat ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Center for Palliative Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPH NODE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEPTOR BINDING; TISSUE DISTRIBUTION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHEMOKINES, CXC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; LYMPH NODES; MALE; RNA, MESSENGER;

EID: 0033543094     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310359     Document Type: Article

References (72)

1. Sattentau QJ and Weiss RA: The CD4 antigen: Physiological ligand and HIV receptor. Cell 1988;52:631-633.
2. Littman DR: Chemokine receptors: Keys to AIDS pathogenesis? Cell 1998;93:677-680.
3. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
4. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J. and Springer TA: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (London) 1996;382:829-833.
5. Oberlein E, Amara A, Bachelerie F, Bessia C, Virelizier JL. Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, and Moser B: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell line-adapted HIV-1. Nature (London) 1996; 382:833-835.
6. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, DaarES, Doms RW, and O'Brien WA: A small-molecule inhibitor directed against chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997;186:1395-1400.
7. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, and Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85:1149-1158.
8. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, and Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (London) 1996;381:667-873.
9. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature (London) 1996;381:661-666.
10. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, and Berger EA: CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
11. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, and Lusso P: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
12. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM, and Koup RA: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nature Med 1996;2:412-417.
13. Asjo B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, and Fenyö EM: Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986;2:660-662.
14. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, and Tersmette M: Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991;65:356-363.
15. Connor RI, Mohri H, Cao Y, and Ho DD: Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 1993;67:1772-1777.
16. Connor RI and Ho DD: Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 1994;68: 4400-4408.
17. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185: 621-628.
18. Roos MT, de Leeuw NA, Claessen FA, Huisman HG, Kootstra NA, Meyaard L, Schellekens PT, Schuitemaker H, and Miedema F: Viro-immunological studies in acute HIV-1 infection. AIDS 1994;8:1533-1538.
19. Tersmette M, Lange JM, de Goede RE de Wolf F, Eeftink-Schattenkerk JK, Schellekens PT, Coutinho RA, Huisman JG, Goudsmit J, and Miedema F: Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989;1:983-985.
20. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, Goudsmit J, Huisman HG, and Miedema F: Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J Virol 1989;63:2118-2125.
21. Termsette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT, Huisman HG, and Miedema F: Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-2032.
22. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyö EM, and Lusso P: In vitro evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Med 1997;3:1259-1265.
23. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, and Ho DD: Genotypic and phenotypie characterization of HIV-1 patients with primary infection. Science 1993;261:1179-1181.
24. Richman DD and Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994;169:968-974.
25. Root M, van't Wout AB, Kootstra NA, de Goede RE, Termsette M. and Schuitemaker H: Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996;173:349-354.
26. Fauci AS: Host factors and the pathogenesis of HIV-induced disease. Nature (London) 1996;384:529-534.
27. Miedema F, Meyaard L, Koot M, Klein MR, Roos MT, Groenink M, Fouchier RA, Van't Wout AB, Tersmette M, and Schellekens PT: Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev 1994;140:35-72.
28. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, and Springer TA: A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184:1101-1109.
29. Aiuti A, Webb IJ, Bleul C, Springer T, and Gutierreez-Ramos JC: The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997;185:111-120.
30. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, and Honjo T: Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 1995;28:495-500.
31. Lacey SF, McDanal CB, Horuk R, and Greenberg ML: The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8+ T cell suppression of syncytia-inducing strains of HIV-1. Proc Natl Acad Sci USA 1997;94:9842-9847.
32. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, and Lapidot T: Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283:845-848.
33. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, and Moore JP: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med 1998;4:72-77.
34. Bakshi SS, Zhang L, Ho D, Than S, and Pahwa SG: Distribution of CCR5delta32 in human immunodeficiency virus-infected children and its relationship to disease course. Clin Diagn Lab Immunol 1998;5:38-40.
35. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE, O'Connell P, Tyron V, Clark RA, Dolan MJ, and Ahuja SK: Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nature Med 1998;4:786-793.
36. Mummidi S, Ahuja SS, McDaniel BL, and Ahuja SK: The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with 5′-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J Biol Chem 1997;272:30662-30671.
37. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vitttnghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, and O'Brien SJ: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-1862.
38. de Roda Husman AM, Koot M, Cornelissen M, Keep IP, Brouwer M, Broersen SM, Bakker M, Roos MT, Prins M, de Wolf F, Coutinho RA, Miedema F, Goudsmit J, and Schuitemaker H: Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127:882-890.
39. Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, and Sheppard HW: The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nature Med 1997;3:1160-1162.
40. Visco-Comandini U, Hultgren C, Brostrom C, Birk M, Kim S, and Sallberg M: Human immunodeficiency virus type 1 disease progression. CCR5 genotype, and specific immune responses. Clin Diagn Lab Immunol 1998;5:463-466.
41. Katzenstein TL, Eugen-Olsen J, Hofmann B, Benfield T, Pedersen C, Iversen AK, Sorensen AM, Garred P, Koppelhus U, Svejgaard A, and Gerstoft J: HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of infection than do patients with the wild type. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:10-14.
42. Eugen-Olsen J, Iversen AK, Garred P, Koppelhus U, Pedersen C, Benfield TL, Sorensen AM, Katzenstein T, Dickmeiss E, Gerstoft J, Skinhoj P, Svejgaard A, Nielsen JO, and Hofmann B: Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997;11:305-310.
43. Morawetz RA, Rizzardi GP, Glauser D, Rutschmann O, Hirschel B, Perrin L, Opravil M, Flepp M, von Overbeck J, Glauser MP, Ghezzi S, Vicenzi E, Poli G, Lazzarin A, and Pantaleo G: Genetic polymorphism of CCR5 gene and HIV disease: The heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Eur J Immunol 1997;27: 3223-3227.
44. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW, and O'Brien SJ: Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997;277: 959-965.
45. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, Deutsch L, Phair J, Neumann AU, and Ho DD: A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nature Med 1998;4:350-353.
46. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JM, Martinez AC, O'Brien SJ, Dean M, Collman RG, and Doms RW: Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1998;72: 7450-7458.
47. Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennets BH, Newcombe NR, Benson EM, Carr A, Cooper DA, and Kaldor JM: Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. AIDS 1997;11:1833-1838.
48. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, and Koup RA: The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996;2:1240-1243.
49. Carrington M, Kissner T, Gerrard B, Ivanov S, O'Brien SJ, and Dean M: Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997;61:1261-1267.
50. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D, Buchbinder S, Vittinghoff E, Goedert JJ, O'Brien TR, Jacobson LP, Detels R, Donfield S, Willoughby A, Gomperts E, Vlahov D, Phair J, and O' Brien SJ: Genetic restriction of AIDS pathogenesis by an SDE-1 chemokine gene variant. Science 1998;279:389-393.
51. Karr L, Panoskaltsis-Mortari A, Li J, Devore-Carter D, Weaver CT, and Bucy RP: In situ hybridization for cytokine mRNA with digoxigenin labeled riboprobes: Sensitivity of detection and double label applications. J Immunol Methods 1995;182:93-106.
52. Panoskaltsis-Mortari A and Bucy RP: In Situ hybridization with digoxigenin-labeled RNA probes: Facts and artifacts. BioTechniques 1995;18:300-307.
53. Taylor JM, Fahey JL, Detels R, and Giorgi JV: CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: Which to choose and how to use. J Acquir Immune Defic Syndr 1989;2:114-124.
54. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, Nishanian P, and Giorgi JV: The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-172.
55. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, and Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 1995;373:117-122.
56. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995;373:123-126.
57. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, and Fischl MA: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-733.
58. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, and Chodakewitz JA: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
59. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, and Fauci AS: Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:9838-9842.
60. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, and Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 1993;362:355-358.
61. Pantaleo G, Graziosi C, Demarest JF, Cohen OJ, Vaccarezza M, Gantt K, Muro-Cacho CA, and Fauci AS: Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev 1994;140:105-130.
62. Cohen OJ, Pantaleo G, Schwartzentruber DJ, Graziosi C, Vaccarezza M, and Fauci AS: Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(Suppl. 1):S6-S14.
63. Soontornniyomkij V, Wang G, Kapadia SB, Achim CL, and Wiley CA: Confocal microscopy assessment of lymphoid tissues with follicular hyperplasia from patients infected with human immunodeficiency virus type 1. Arch Pathol Lab Med 1998;122: 534-538.
64. Mellors J, Rinaldo C, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
65. O'Brien W, Hartigan P, and Martin D: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Rapid and simple PCR assay for quantitation of HIV-1 RNA in plasma: Application to acute retroviral infection. N Engl J Med 1996;334:426-431.
66. Kakkanaiah VN, Ojo-Amaize EA, and Peter JB: Concentrations of circulating beta-chemokines do not correlate with viral load in human immunodeficiency virus-infected individuals. Clin Diagn Lab Immunol 1998;5:499-502.
67. Krowka JF, Gesner ML, Ascher MS, and Sheppard HW: Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals. Clin Immunol Immunopathol 1997;85:21-27.
68. Kitchen SG and Zack JA: CXCR4 expression during lymphopoiesis: Implications for human immunodeficiency virus type 1 infection of the thymus. J Virol 1997;71:6928-6934.
69. Carroll RG, Riley JL, Levine BL, Feng Y, Kaushal S, Ritchey DW, Bernstein W, Weislow OS, Brown CR, Berger EA, June CH, and St. Louis DC: Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 1997;276:273-276.
70. Bleul CC, Wu L, Hoxie JA, Springer TA, and Mackay CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-1930.
71. Ostrowski MA, Krakauer DC, Li Y, Justement SJ, Learn G, Ehler LA, Stanley SK, Nowak M, and Fauci AS: Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol 1998;72:7772-7784.
72. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, and Mann DL: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med 1996;2:405-411.